TN2009000145A1 - Compositions and methods for modulating c-kit and pdgfr receptors - Google Patents

Compositions and methods for modulating c-kit and pdgfr receptors

Info

Publication number: TN2009000145A1
Authority: TN; Tunisia
Prior art keywords: methods; raf; kit; pdgfr; compounds
Prior art date: 2006-10-20

Application number

TNP2009000145A

Other languages

English (en)

Inventor

Donatella Chianelli

Christopher Cow

Yun He

Songchun Jiang

Xiaolin Li

Xiaodong Liu

Zuosheng Liu

Jon Loren

Valentina Molteni

Juliet Nabakka

Pingda Ren

Taebo Sim

Xiaodong Wang

Shuli You

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-20

Filing date

2009-04-17

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39027274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-17 Application filed by Irm Llc filed Critical Irm Llc

2010-10-18 Publication of TN2009000145A1 publication Critical patent/TN2009000145A1/fr

Links

102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
101150093908 PDGFRB gene Proteins 0.000 title 1
239000000203 mixture Substances 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
-1 CSFlR Proteins 0.000 abstract 2
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 2
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 2
230000002159 abnormal effect Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 1
102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 abstract 1
101150036586 FES gene Proteins 0.000 abstract 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 abstract 1
101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 1
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 abstract 1
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 abstract 1
101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 abstract 1
101150028321 Lck gene Proteins 0.000 abstract 1
108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 1
102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 1
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 abstract 1
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102100039810 Protein-tyrosine kinase 6 Human genes 0.000 abstract 1
108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 abstract 1
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 abstract 1
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
101150046814 SAPK2 gene Proteins 0.000 abstract 1
108060006706 SRC Proteins 0.000 abstract 1
101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 abstract 1
108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
102100031167 Tyrosine-protein kinase CSK Human genes 0.000 abstract 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
239000003909 protein kinase inhibitor Substances 0.000 abstract 1
102000009929 raf Kinases Human genes 0.000 abstract 1
108010077182 raf Kinases Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Oncology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Virology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)

TNP2009000145A 2006-10-20 2009-04-17 Compositions and methods for modulating c-kit and pdgfr receptors TN2009000145A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86243006P	2006-10-20	2006-10-20
PCT/US2007/081538 WO2008051757A1 (fr)	2006-10-20	2007-10-16	Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr)

Publications (1)

Publication Number	Publication Date
TN2009000145A1 true TN2009000145A1 (en)	2010-10-18

Family

ID=39027274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000145A TN2009000145A1 (en)	2006-10-20	2009-04-17	Compositions and methods for modulating c-kit and pdgfr receptors

Country Status (25)

Country	Link
US (2)	US7678792B2 (fr)
EP (1)	EP2076513A1 (fr)
JP (1)	JP2010506948A (fr)
KR (1)	KR101079520B1 (fr)
CN (1)	CN101528744A (fr)
AR (1)	AR063343A1 (fr)
AU (1)	AU2007309279B2 (fr)
BR (1)	BRPI0718162A2 (fr)
CA (1)	CA2667010A1 (fr)
CL (1)	CL2007003005A1 (fr)
CO (1)	CO6170361A2 (fr)
CR (1)	CR10717A (fr)
EA (1)	EA200900573A1 (fr)
EC (1)	ECSP099353A (fr)
IL (1)	IL197875A0 (fr)
MA (1)	MA30888B1 (fr)
MX (1)	MX2009004141A (fr)
NI (1)	NI200900061A (fr)
NO (1)	NO20091949L (fr)
PE (1)	PE20081262A1 (fr)
SM (1)	SMP200900027B (fr)
TN (1)	TN2009000145A1 (fr)
TW (1)	TW200825081A (fr)
WO (1)	WO2008051757A1 (fr)
ZA (1)	ZA200902711B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2477604A1 (fr)	2002-03-13	2003-09-25	Signum Biosciences, Inc.	Modulation de la methylation de proteines et du phosphate des phosphoproteines
WO2006084033A1 (fr)	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions et procedes pour l'amelioration de la fonction cognitive
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI409081B (zh)	2006-11-09	2013-09-21	Alcon Res Ltd	用於藥物輸送之水不溶性聚合物基質
TWI498115B (zh) *	2007-12-27	2015-09-01	Daiichi Sankyo Co Ltd	咪唑羰基化合物
CA2714700C (fr)	2008-02-22	2013-07-30	Irm Llc	Composes et compositions heterocycliques comme inhibiteurs de c-kit et pdgfr kinase
JP5607025B2 (ja)	2008-04-21	2014-10-15	シグナムバイオサイエンシーズ，インコーポレイテッド	化合物、組成物およびそれらを作製する方法
FR2930552B1 (fr) *	2008-04-24	2012-10-12	Centre Nat Rech Scient	N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EP2297097A2 (fr) *	2008-06-11	2011-03-23	Irm Llc	Composés et compositions utiles pour le traitement de la malaria
WO2010017331A1 (fr) *	2008-08-05	2010-02-11	George Mason Intellectual Properties, Inc.	Altérations de voie de signalisation et élévations de médicament cible dans le cancer colorectal métastasique métachrone primaire comparé à une maladie non métastasique
CN102256493A (zh) *	2008-10-29	2011-11-23	迪赛孚尔制药有限公司	表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
WO2010071846A2 (fr)	2008-12-19	2010-06-24	Afraxis, Inc.	Composés pour traiter des états neuropsychiatriques
SG173610A1 (en) *	2009-02-13	2011-09-29	Fovea Pharmaceuticals Sa	[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
JP2013507395A (ja)	2009-10-09	2013-03-04	アフラクシス・インコーポレイテッド	Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
NZ600857A (en)	2010-01-29	2014-06-27	Boehringer Ingelheim Int	Substituted naphthyridines and their use as syk kinase inhibitors
US9181238B2 (en)	2010-02-05	2015-11-10	Novartis Ag	N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
US9540443B2 (en) *	2011-01-26	2017-01-10	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies
WO2012148994A1 (fr)	2011-04-25	2012-11-01	Usher Iii Initiative	Pyrazolopyridazines et méthodes de traitement des maladies dégénératives de la rétine et la perte d'audition associée au syndrome de usher
CN103827090B (zh)	2011-07-26	2016-04-20	勃林格殷格翰国际有限公司	取代的喹啉及其作为药物的用途
AP2014007595A0 (en) *	2011-09-30	2014-04-30	Kineta Inc	Anti-viral compounds
ES2670667T3 (es)	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
KR20150008406A (ko)	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
PT2861579T (pt)	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
WO2013171641A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
DK3366293T3 (da) *	2012-06-07	2020-06-15	Deciphera Pharmaceuticals Llc	Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme
CN116574185A (zh)	2012-07-25	2023-08-11	塞尔德克斯医疗公司	抗kit抗体及其用途
US9227976B2 (en)	2012-10-25	2016-01-05	Usher Iii Initiative, Inc.	Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2014302458A1 (en) *	2013-06-26	2015-12-24	Proteostasis Therapeutics, Inc.	Methods of modulating CFTR activity
GB201401886D0 (en)	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
US9745292B2 (en)	2014-03-13	2017-08-29	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
WO2015138909A1 (fr)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Composés, compositions et procédés pour augmenter l'activité du cftr
CN113908269A (zh)	2014-05-23	2022-01-11	塞尔德克斯医疗公司	嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3157917B1 (fr)	2014-06-19	2020-03-18	Proteostasis Therapeutics, Inc.	Composés, compositions et procédés pour augmenter l'activité du cftr
CN111170998B (zh)	2014-11-05	2023-04-11	益方生物科技(上海)股份有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
US10392378B2 (en)	2014-12-23	2019-08-27	Proteostasis Therapeutics, Inc.	Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 (en)	2014-12-23	2019-07-09	Proteostasis Therapeutics, Inc.	Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr)	2014-12-23	2017-10-31	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
US10738011B2 (en)	2014-12-23	2020-08-11	Proteostasis Therapeutics, Inc.	Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en)	2015-07-24	2020-02-04	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods of increasing CFTR activity
CN105664178B (zh) *	2015-09-24	2019-08-20	洪健	Syk作为肝纤维化/硬化治疗靶点的应用
BR112018007021B1 (pt)	2015-10-06	2024-01-09	Proteostasis Therapeutics, Inc	Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
CN107286077B (zh) *	2016-04-01	2021-04-02	合肥中科普瑞昇生物医药科技有限公司	一种选择性的c-kit激酶抑制剂
MA43775A (fr)	2016-04-07	2021-05-05	Proteostasis Therapeutics Inc	Analogues du ivacaftor conentant des atomes de silicium
MA45397A (fr)	2016-06-21	2019-04-24	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
EP3535243B1 (fr) *	2016-11-04	2021-12-15	Auckland Uniservices Limited	Dérivés de 9h-xanthén-9-one, 9h-thioxanthen-9-one et acridin-9(10h)-one substitués et composés similaires en tant qu'inhibiteurs csf-1r pour le traitement du cancer
AU2018238138A1 (en)	2017-03-21	2019-10-17	Arbutus Biopharma Corporation	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN110869017B (zh)	2017-05-12	2023-05-05	英安塔制药有限公司	细胞凋亡信号调节激酶1抑制剂及其使用方法
CA3065365C (fr) *	2017-05-30	2025-09-16	Deciphera Pharmaceuticals, Llc	Utilisation de 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridine-3-yl]-2-fluorophenyl]-3-phenyluree et de ses analogues pour le traitement de cancers associes a des anomalies genetiques au niveau du recepteur alpha du facteur de croissance derive des plaquettes
WO2019056990A1 (fr) *	2017-09-20	2019-03-28	浙江海正药业股份有限公司	Dérivé de 1,2-dihydro-1,6-naphtyridine, son procédé de préparation et son application en médecine
MX2020003242A (es)	2017-09-22	2020-09-18	Jubilant Epipad LLC	Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en)	2017-10-18	2022-08-25	Jubilant Epipad LLC	Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko)	2017-11-06	2020-07-15	주빌런트 프로델 엘엘씨	Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt)	2017-11-24	2020-11-17	Jubilant Episcribe Llc	composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
KR102708177B1 (ko)	2018-01-31	2024-09-23	데시페라 파마슈티칼스, 엘엘씨.	위장관 기질 종양의 치료를 위한 병용 요법
IL276398B2 (en)	2018-01-31	2026-03-01	Deciphera Pharmaceuticals Llc	Combination therapy for mastocytosis
SG11202008950PA (en)	2018-03-13	2020-10-29	Jubilant Prodel LLC	Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3787621B1 (fr)	2018-05-02	2024-12-18	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant des tétrazoles et leurs méthodes d'utilisation
US10968199B2 (en) *	2018-08-22	2021-04-06	Enanta Pharmaceuticals, Inc.	Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
RU2771526C1 (ru)	2018-09-14	2022-05-05	Аббиско Терапеутикс Ко., Лтд.	Ингибитор fgfr, метод его получения и его применение
WO2020106707A1 (fr)	2018-11-19	2020-05-28	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation
CN119684457A (zh)	2018-11-26	2025-03-25	四十七有限责任公司	针对c-kit的人源化抗体
EP3938363A1 (fr)	2019-03-11	2022-01-19	Teva Pharmaceuticals International GmbH	Formes à l'état solide de riprétinib
US11466033B2 (en)	2019-03-25	2022-10-11	Enanta Pharmaceuticals, Inc.	Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
LT4013412T (lt)	2019-08-12	2026-03-25	Deciphera Pharmaceuticals, Llc	Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
PT4013412T (pt)	2019-08-12	2026-03-18	Deciphera Pharmaceuticals Llc	Ripretinib para o tratamento de tumores estromais gastrointestinais
JP7580123B2 (ja) *	2019-08-25	2024-11-11	国立大学法人山口大学	血管新生関連疾患の予防又は治療用医薬組成物
HRP20231699T1 (hr)	2019-12-30	2024-05-10	Deciphera Pharmaceuticals, Llc	Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh)	2019-12-30	2024-08-16	德西费拉制药有限责任公司	1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
TW202204354A (zh) *	2020-04-02	2022-02-01	美商普雷辛肯公司	用於ｃｓｋ調節之化合物及方法以及其說明
IL299695A (en)	2020-07-09	2023-03-01	Usher Iii Initiative Inc	Treatment of cancer, inflammatory diseases and autoimmune diseases
MX2023005747A (es)	2020-11-18	2023-07-28	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CN115108997A (zh) *	2021-03-22	2022-09-27	南开大学	一类具抑菌活性的磺酰脲类化合物的合成与应用
CA3233636A1 (fr) *	2021-09-29	2023-04-06	Repare Therapeutics Inc.	Composes n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitues)carboxamide (substitue) et leur utilisation pour inhiber la polymerase theta humaine
KR20240113496A (ko)	2021-12-03	2024-07-22	데시페라 파마슈티칼스, 엘엘씨.	Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
US11814384B2 (en)	2022-02-03	2023-11-14	Kinnate Biopharma Inc.	Inhibtors of Raf kinases
EP4572758A1 (fr) *	2022-08-19	2025-06-25	Purdue Research Foundation	Inhibiteurs des interactions protéine-protéine
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
KR20250108598A (ko) *	2022-09-29	2025-07-15	리페어 세라퓨틱스 인크.	N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (1,3-티아졸릴)](치환된)카복스아마이드 화합물, 약제학적 조성물, 그리고 아마이드 화합물의 제조 방법 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001292320A1 (en)	2000-10-02	2002-04-15	Tanabe Seiyaku Co., Ltd.	Benzylamine compound, process for producing the same, and intermediate therefor
AU2004279427B2 (en)	2003-10-08	2008-07-03	Irm Llc	Compounds and compositions as protein kinase inhibitors
AU2005325676A1 (en) *	2004-12-23	2006-08-03	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
WO2006071940A2 (fr) *	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Modulateurs d'enzymes et traitements
US20090312321A1 (en) *	2006-05-15	2009-12-17	Irm Llc	Compositions and methods for fgf receptor kinases inhibitors
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BRPI0718029A2 (pt) *	2006-11-06	2013-11-26	Supergen Inc	Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase

2007
- 2007-10-16 EA EA200900573A patent/EA200900573A1/ru unknown
- 2007-10-16 AU AU2007309279A patent/AU2007309279B2/en not_active Ceased
- 2007-10-16 JP JP2009533484A patent/JP2010506948A/ja active Pending
- 2007-10-16 CA CA002667010A patent/CA2667010A1/fr not_active Abandoned
- 2007-10-16 EP EP07844322A patent/EP2076513A1/fr not_active Ceased
- 2007-10-16 CN CNA2007800390373A patent/CN101528744A/zh active Pending
- 2007-10-16 KR KR1020097008062A patent/KR101079520B1/ko not_active Expired - Fee Related
- 2007-10-16 US US11/873,196 patent/US7678792B2/en not_active Expired - Fee Related
- 2007-10-16 MX MX2009004141A patent/MX2009004141A/es active IP Right Grant
- 2007-10-16 BR BRPI0718162-0A patent/BRPI0718162A2/pt not_active IP Right Cessation
- 2007-10-16 WO PCT/US2007/081538 patent/WO2008051757A1/fr not_active Ceased
- 2007-10-19 TW TW096139384A patent/TW200825081A/zh unknown
- 2007-10-19 PE PE2007001422A patent/PE20081262A1/es not_active Application Discontinuation
- 2007-10-19 AR ARP070104639A patent/AR063343A1/es unknown
- 2007-10-19 CL CL200703005A patent/CL2007003005A1/es unknown
2009
- 2009-03-26 IL IL197875A patent/IL197875A0/en unknown
- 2009-04-16 CR CR10717A patent/CR10717A/es not_active Application Discontinuation
- 2009-04-17 CO CO09039151A patent/CO6170361A2/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000145A patent/TN2009000145A1/fr unknown
- 2009-04-20 NI NI200900061A patent/NI200900061A/es unknown
- 2009-04-20 SM SM200900027T patent/SMP200900027B/it unknown
- 2009-04-20 ZA ZA200902711A patent/ZA200902711B/xx unknown
- 2009-05-13 MA MA31869A patent/MA30888B1/fr unknown
- 2009-05-19 NO NO20091949A patent/NO20091949L/no not_active Application Discontinuation
- 2009-05-20 EC EC2009009353A patent/ECSP099353A/es unknown
- 2009-12-02 US US12/629,665 patent/US8106068B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW200825081A (en)	2008-06-16
NO20091949L (no)	2009-05-19
CN101528744A (zh)	2009-09-09
PE20081262A1 (es)	2008-10-29
SMP200900027B (it)	2010-01-19
CR10717A (es)	2009-07-02
ZA200902711B (en)	2010-05-26
MA30888B1 (fr)	2009-11-02
CO6170361A2 (es)	2010-06-18
US20080176846A1 (en)	2008-07-24
AU2007309279A1 (en)	2008-05-02
BRPI0718162A2 (pt)	2013-11-26
WO2008051757A1 (fr)	2008-05-02
JP2010506948A (ja)	2010-03-04
ECSP099353A (es)	2009-06-30
US8106068B2 (en)	2012-01-31
US20100081656A1 (en)	2010-04-01
AU2007309279B2 (en)	2011-03-24
IL197875A0 (en)	2009-12-24
MX2009004141A (es)	2009-05-01
KR20090054477A (ko)	2009-05-29
NI200900061A (es)	2010-03-10
CA2667010A1 (fr)	2008-05-02
US7678792B2 (en)	2010-03-16
SMAP200900027A (it)	2009-07-14
EA200900573A1 (ru)	2009-10-30
KR101079520B1 (ko)	2011-11-03
AR063343A1 (es)	2009-01-21
CL2007003005A1 (es)	2008-05-23
EP2076513A1 (fr)	2009-07-08

Publication	Publication Date	Title
TN2009000145A1 (en)	2010-10-18	Compositions and methods for modulating c-kit and pdgfr receptors
MX2010002005A (es)	2010-03-11	Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
TN2010000087A1 (en)	2011-09-26	5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
TNSN06406A1 (en)	2008-02-22	Compounds and compositions as protein kinase inhibitors
WO2005034869A3 (fr)	2005-07-07	Composes et compositions convenant comme inhibiteurs de proteine-kinases
TW200637547A (en)	2006-11-01	Compounds and compositions as protein kinase inhibitors
MX2008001969A (es)	2008-04-11	Compuestos y composiciones como inhibidores de proteina cinasa.
PL2027123T3 (pl)	2011-09-30	Związki i kompozycje jako inhibitory kinaz białkowych
WO2006124731A3 (fr)	2007-03-29	Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
MX2009003456A (es)	2009-04-14	Compuestos y composiciones como inhibidores de proteina cinasa.
MX2008002165A (es)	2008-04-29	Compuestos y composiciones como inhibidores de la proteina cinasa.
EA200901654A1 (ru)	2010-06-30	Ингибиторы и способы с их использованием
EA201000003A1 (ru)	2010-06-30	Ингибиторы протеинкиназ и способы их применения
MX2009003649A (es)	2009-04-22	Inhibidores de cinasa de proteina y metodos para utilizarlos.
TW200726766A (en)	2007-07-16	Compounds and compositions as protein kinase inhibitors
MX2007005547A (es)	2007-07-05	Compuestos y composiciones como inhibidores de la proteina cinasa.
WO2005039486A3 (fr)	2006-03-16	Composes et compositions servant d'inhibiteurs de la proteine kinase
BRPI0512422A (pt)	2008-03-04	compostos e composições como inobidores da proteìna quinase
WO2005030151A3 (fr)	2005-09-09	Composes et compositions utiles comme inhibiteurs de la proteine kinase
DOP2009000083A (es)	2009-06-30	Composiciones y metodos para modular recpetores de pdgfr y c-kit
TH98294A (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์
TH98294B (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์